8-K/A filing — Axogen, Inc. (AXGN)
Filed: 2026-09-10 AccNo: 0001628280-26-061393 Size: 3 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
8-K filing — Axogen, Inc. (AXGN)
Filed: 2026-09-10 AccNo: 0001628280-26-061208 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair
Axogen is acquiring BioCircuit Technologies for $200 million to add sutureless NerveTape to its portfolio, funded by a public stock offering.
Axogen shares are trading lower. The company announced the $200 million cash acquisition of BioCircuit, and a $208.7 million public offering of common stock.
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
Axogen announced a definitive agreement to acquire BioCircuit Technologies for $200 million in cash, adding NerveTape™, the first FDA-approved sutureless device for peripheral nerve repair. The acquisition is expected to close in Q4 2026 and be accretive to revenue growth, adjusted EBITDA margin, and adjusted EPS in the first year, while maintaining positive free cash flow. Axogen will fund the purchase through a $208.7 million public stock offering.